Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
NXS Stock Overview
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia.
Next Science Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.98 |
52 Week High | AU$1.50 |
52 Week Low | AU$0.70 |
Beta | 0.81 |
1 Month Change | 26.28% |
3 Month Change | 11.93% |
1 Year Change | -30.88% |
3 Year Change | -65.44% |
5 Year Change | n/a |
Change since IPO | -27.04% |
Recent News & Updates
Shareholder Returns
NXS | AU Medical Equipment | AU Market | |
---|---|---|---|
7D | 1.5% | -0.4% | 1.8% |
1Y | -30.9% | -20.6% | -5.7% |
Return vs Industry: NXS underperformed the Australian Medical Equipment industry which returned -19.2% over the past year.
Return vs Market: NXS underperformed the Australian Market which returned -6.5% over the past year.
Price Volatility
NXS volatility | |
---|---|
NXS Average Weekly Movement | 11.6% |
Medical Equipment Industry Average Movement | 11.4% |
Market Average Movement | 10.6% |
10% most volatile stocks in AU Market | 17.7% |
10% least volatile stocks in AU Market | 4.6% |
Stable Share Price: NXS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: NXS's weekly volatility (12%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | n/a | Judy Mitchell | https://www.nextscience.com |
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections.
Next Science Limited Fundamentals Summary
NXS fundamental statistics | |
---|---|
Market Cap | AU$211.57m |
Earnings (TTM) | -AU$13.29m |
Revenue (TTM) | AU$12.71m |
16.6x
P/S Ratio-15.9x
P/E RatioIs NXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NXS income statement (TTM) | |
---|---|
Revenue | US$8.95m |
Cost of Revenue | US$2.01m |
Gross Profit | US$6.94m |
Other Expenses | US$16.29m |
Earnings | -US$9.35m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 25, 2022
Earnings per share (EPS) | -0.044 |
Gross Margin | 77.56% |
Net Profit Margin | -104.49% |
Debt/Equity Ratio | 0% |
How did NXS perform over the long term?
See historical performance and comparison